

115TH CONGRESS
1ST SESSION

H. R. 3964

To amend the Controlled Substances Act to establish additional registration requirements for prescribers of opioids, and for other purposes.

IN THE HOUSE OF REPRESENTATIVES

OCTOBER 5, 2017

Mr. ROE of Tennessee (for himself, Ms. KUSTER of New Hampshire, Mr. MACARTHUR, Mrs. RADEWAGEN, and Miss GONZÁLEZ-COLÓN of Puerto Rico) introduced the following bill; which was referred to the Committee on Energy and Commerce, and in addition to the Committee on the Judiciary, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned

A BILL

To amend the Controlled Substances Act to establish additional registration requirements for prescribers of opioids, and for other purposes.

1 *Be it enacted by the Senate and House of Representa-*
2 *tives of the United States of America in Congress assembled,*

3 **SECTION 1. SHORT TITLE.**

4 This Act may be cited as the “Opioid Addiction Pre-
5 vention Act of 2017”.

1 **SEC. 2. REGISTRATION REQUIREMENTS FOR PRESCRIBERS.**

2 Section 303 of the Controlled Substances Act (21
3 U.S.C. 823) is amended by adding at the end the fol-
4 lowing:

5 “(k)(1) The Attorney General shall not register, or
6 renew the registration of, a practitioner under subsection
7 (f) who is licensed under State law to prescribe controlled
8 substances in schedule II, III, or IV, unless the practi-
9 tioner submits to the Attorney General, for each such reg-
10 istration or renewal request, a certification that the practi-
11 tioner, during the applicable registration period, will not
12 prescribe, for the initial treatment of acute pain, any
13 schedule II, III, or IV opioid, other than an opioid pre-
14 scription described in paragraph (3)—

15 “(A) without firstly or concomitantly pre-
16 scribing one or more non-opioid analgesics, if there
17 are no contraindications to such analgesics;

18 “(B) without clearly stating on the prescription
19 the diagnosis for which the opioid is prescribed;

20 “(C) unless the prescribed opioid dose is the
21 lowest effective dose;

22 “(D) an extended release or long acting formu-
23 lation of the opioid; and

24 “(E) in an amount in excess of the lesser of—

25 “(i) a 10-day supply (for which no refill is
26 available); or

1 “(ii) an opioid prescription limit estab-
2 lished under State law.

3 “(2) In this subsection, the term ‘acute pain’—

4 “(A) means pain with abrupt onset and caused
5 by a discrete injury, surgical procedure, or other ill-
6 ness of limited duration; and

7 “(B) does not include—

8 “(i) chronic pain;

9 “(ii) pain being treated as part of cancer
10 care;

11 “(iii) hospice or other end-of-life care; or

12 “(iv) pain being treated as part of pallia-
13 tive care.

14 “(3) An opioid prescription described in this para-
15 graph is a prescription—

16 “(A) for a schedule II, III, or IV opioid drug
17 approved by the Food and Drug Administration for
18 an indication for the treatment of addiction; and

19 “(B) that is for the treatment of addiction.”.

○